| RESEARCH ARTICLE |
|
| Year : 2022 | Volume
: 1
| Issue : 1 | Page : 20-30 |
|
|
Management of Meige’s syndrome by facial and trigeminal nerve combing followed by transplantation of autologous adipose-derived mesenchymal stem cells: a prospective nonrandomized controlled study
Jin Zhu1, Bei-Yao Gao2, Xin Zhang1, Cheng-Cheng Sun3, Hua Zhao1, Ming Chen1, Yan Yuan1, Ping Zhou1, Yan-Li Luo4, Dongsheng Xu5, Shi-Ting Li1
1 Department of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Department of Rehabilitation Medicine, China-Japan Friendship Hospital, Beijing, China
3 Tongji University School of Medicine, Shanghai, China
4 Department of Psychological Medicine, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
5 School of Rehabilitation Science; Institute of Rehabilitation Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Correspondence Address:
Dongsheng Xu
School of Rehabilitation Science; Institute of Rehabilitation Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai
China
Shi-Ting Li
Department of Neurosurgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
China
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2773-2398.340141
|
|
|
Increasing attention has recently been focused on reducing abnormal neuroexcitability in patients with Meige’s syndrome using nerve combing surgery. However, nerve injury caused by nerve combing is of critical concern. Animal studies have shown that stem cells can repair cranial nerves; autologous adipose-derived mesenchymal stem cells have been proved to be safe and effective in clinical trials. A total of 38 patients with Meige’s syndrome were enrolled in this prospective nonrandomized controlled study and divided into a non–stem cell group (n = 30) and a stem cell group (n = 8). Patients in the non-stem cell group underwent facial and trigeminal nerve combing only; patients in the stem cell group underwent adipose-derived mesenchymal stem cell implantation after facial and trigeminal nerve combing. A blepharospasm disability index score was used to evaluate effectiveness of the surgery, and a House–Brackmann grade was used to evaluate facial nerve injury. These data were recorded before the operation and at 7 days, 3 months, and 6 months after the operation. The overall improvement percentage of blepharospasm was 93% at 6-month follow-up in the non-stem cell group. A greater number of nerve combing events during the operation led to better outcomes but increased risk of facial paralysis. Patients in the stem cell group had better facial nerve function at the 6-month follow-up (House–Brackmann grade, P = 0.003) and better blepharospasm improvement at 3 and 6 months than those in the non–stem cell group (blepharospasm disability index score, P = 0.003 and P < 0.001, respectively). Cerebrospinal fluid protein analysis showed that levels of several cytokines were significantly increased after adipose-derived mesenchymal stem cell transplantation, including interleukin-6 (P < 0.01) and interferon gamma-induced protein 10 (P < 0.0001) and the growth factors insulin-like growth factor-1 (P < 0.0001), insulin-like growth factor-binding protein-1 (P < 0.0001), growth/differentiation factor-15 (P < 0.001), and angiopoietin-like 4 (P < 0.001). Facial and trigeminal nerve combing combined with adipose-derived mesenchymal stem cell transplantation is a safe and effective remedy to improve recovery from Meige’s syndrome.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
